Dihexa is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
March 31, 2004: The Ministry Delegate for Parity and Professional Equality gains its autonomy. May 26, 2004: Law concerning divorce; the protection of the spouse victim of violence is taken into account. July 1, 2004: Decree concerning the conditions for performing voluntary terminations of pregnancy outside healthcare establishments and amending the Public Health Code (second part: Regulatory part). August 6, 2004: Law concerning bioethics. November 24, 2004: Plan to combat violence against women. November 24, 2004: Ordinance concerning the legislative part of the Code on the Entry and Residence of Foreigners and the Right of Asylum. March 23, 2006: Law concerning equal pay between women and men. April 5, 2006: Law on strengthening the prevention and repression of violence within couples or against minors. December 30, 2004: Law establishing the French Equal Opportunities and Anti-Discrimination Commission (HALDE). March 17, 2005: Decree concerning the family reunification of foreigners for the application of Book IV of the Code on the Entry and Residence of Foreigners and the Right of Asylum. April 2, 2005: Orientation and Program Law for the Future of the School, which emphasizes that it must "promote coeducation and equality between men and women." June 2, 2005: Creation of the Ministry Delegate for Social Cohesion and Parity. July 4, 2005: Ordinance reforming filiation. August 2, 2005: Law in favor of small and medium-sized enterprises; it notably includes provisions concerning the status of the collaborating spouse.
NAD+ + ubiquinol This enzyme is a flavoprotein (FAD). It belongs to the family of oxidoreductases, specifically those acting on NADH or NADPH with other acceptors. The systematic name of this enzyme class is NADH:(quinone-acceptor) oxidoreductase. Other names in common use include reduced nicotinamide adenine dinucleotide (quinone) dehydrogenase, NADH-quinone oxidoreductase, NADH ubiquinone oxidoreductase, DPNH-menadione reductase, D-diaphorase, and NADH2 dehydrogenase (quinone), and mitochondrial (mt) complex I. This enzyme participates in oxidative phosphorylation. Several compounds are known to inhibit this enzyme, including AMP, and 2,4-dinitrophenol. NADH dehydrogenase is involved in the first step of the electron transport chain of oxidative phosphorylation (OXPHOS). Any change in the electron transport component caused by a mutation might effect the normal electron flow. This might be leading "an increase of bifurcation and generation of superoxidase radicals and increase oxidative stress in various types of cancer cells."
The substrates of this enzyme are mevalonic acid, coenzyme A, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), reduced NADH, and two protons. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R)-mevalonate:NAD+ oxidoreductase (CoA-acylating). Other names in common use include beta-hydroxy-beta-methylglutaryl coenzyme A reductase, beta-hydroxy-beta-methylglutaryl CoA-reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and hydroxymethylglutaryl coenzyme A reductase.
The Bailey peptide synthesis is a name reaction in organic chemistry developed 1949 by J. L. Bailey. It is a method for the synthesis of a peptide from α-amino acid-N-carboxylic acid anhydrides (NCAs) and amino acids or peptide esters. The reaction is characterized by short reaction times and a high yield of the target peptide. The reaction can be carried out at low temperatures in organic solvents. The residues R1 and R2 can be organic groups or hydrogen atoms, R3 is the used amino acid or peptide ester: The reaction mechanism is not known in detail. Supposedly, the reaction begins with a nucleophilic attack of the amino group on the carbonyl carbon of the anhydride group of the N-carboxylic acid anhydride (1). After an intramolecular proton migration, a 1,4-proton shift and the cleavage of carbon dioxide follows, resulting in the peptide bond in the final product (2):
Sources: en.wikipedia.org
=== Brand names === The maleic acid salt of trimebutine is marketed under the trademarks of Antinime, Cineprac, Colospasmyl, Colypan, Crolipsa, Debricol, Debridat, Debretin, Digedrat, Espabion, Gast Reg, Ircolon, Irritratil, Krisxon, Muttifen, Neotina, Polybutin, Sangalina, Trebutel, Tribudat, Tributina, Tribux, Trim, Trimeb, Trimedat, and Trimedine. Combination with medazepam appears to have been marketed.
University of Galway has been awarded the full five QS stars for excellence, and is ranked among the top 1 per cent of universities according to the 2018 QS World University Rankings. These rankings marked the sixth consecutive year that the university's ranking improved by these standards. In 2016 and 2017, the university was ranked ahead of University College Dublin (UCD) and Queen's University Belfast (QUB) in the Academic Ranking of World Universities (ARWU), placing it second among Irish universities — behind only Trinity College Dublin (TCD). Likewise, in the Times Higher Education World University Rankings, Galway was ranked ahead of UCD and behind only TCD. The Sunday Times University Guide has named the university as its "University of the Year" on three occasions. It won the Times's inaugural title in 2002–2003. A second title followed in 2009–2010. Galway won its third title in 2018.
=== Electronation and de-electronation === The electrochemist John Bockris proposed the words electronation and de-electronation to describe reduction and oxidation processes, respectively, when they occur at electrodes. These words are analogous to protonation and deprotonation. IUPAC has recognized the terms electronation and de-electronation.
=== European Union === In August 2021, Foreign Minister Béjar announced Peru's withdrawal, without officially carrying it out, from the Lima Group and support for the International Contact Group of the European Union for a negotiated solution between the regime of Nicolás Maduro and the opposition regarding the Venezuelan crisis. In addition, Béjar announced his intention, as foreign minister, to reconstitute the UNASUR and strengthen the CELAC, although this was not officially carried out.In September 2021, the Peruvian government signed the "Development Objectives Grant Agreement" with the United States Agency for International Development (USAID) to receive 321 million dollars through 2026. The agreement was signed between Foreign Minister Maúrtua and Jene Thomas, USAID mission director, in the presence of U.S. ambassador Lisa Kenna, who before joining the diplomatic service had been an agent of the CIA. During that same month, the Peruvian government signed the United Nations Sustainable Development Cooperation Framework in Peru 2022-2026 for 180 million dollars, with the framework's preparation led by the resident coordinator of the United Nations System (UNS) in the country to "contribute to the efforts of the Government of Peru in fulfilling the 2030 Agenda and the Sustainable Development Goals, as well as the national development priorities with which this roadmap aligns", also establishing "the general guidelines for developing joint work plans between the Government of Peru and twenty-two AFPs [UN Agencies, Funds and Programmes]" over the following five years.
With their repeated –CH2 units, the alkanes constitute a homologous series of organic compounds in which the members differ in molecular mass by multiples of 14.03 u (the total mass of each such methylene bridge unit, which comprises a single carbon atom of mass 12.01 u and two hydrogen atoms of mass ~1.01 u each). Methane is produced by methanogenic archaea and some long-chain alkanes function as pheromones in certain animal species or as protective waxes in plants and fungi. Nevertheless, most alkanes do not have much biological activity. They can be viewed as molecular trees upon which can be hung the more active/reactive functional groups of biological molecules. The alkanes have two main commercial sources: petroleum (crude oil) and natural gas. An alkyl group is an alkane-based molecular fragment that bears one open valence for bonding. They are generally abbreviated with the symbol for any organyl group, R, although Alk is sometimes used to specifically symbolize an alkyl group (as opposed to an alkenyl group or aryl group).
Sources: en.wikipedia.org
Roller chain or bush roller chain is the type of chain drive most commonly used for transmission of mechanical power on many kinds of domestic, industrial and agricultural machinery, including conveyors, wire- and tube-drawing machines, printing presses, cars, motorcycles, and bicycles. It consists of a series of short cylindrical rollers held together by side links. It is driven by a toothed wheel called a sprocket. It is a simple, reliable, and efficient means of power transmission. Sketches by Leonardo da Vinci in the 16th century show a chain with a roller bearing. In 1800, James Fussell patented a roller chain on development of his balance lock and in 1880 Hans Renold patented a bush roller chain.
=== Global market === The global jerky snacks market size was valued at $5.66 billion in 2024. It is expected to reach $8.81 billion by 2033, exhibiting a compound annual growth rate of 4.79% from 2025–2033. North America dominates the market, holding a market share of over 50.0% in 2024.
== Selected publications == Kiessling, Laura L.; Pohl, Nicola L. (1996-02-01). "Strength in numbers: non-natural polyvalent carbohydrate derivatives". Chemistry & Biology. 3 (2): 71–77. doi:10.1016/S1074-5521(96)90280-X. ISSN 1074-5521. PMID 8807830. Ko, Kwang-Seuk; Jaipuri, Firoz A.; Pohl, Nicola L. (2005-09-28). "Fluorous-Based Carbohydrate Microarrays". Journal of the American Chemical Society. 127 (38): 13162–13163. Bibcode:2005JAChS.12713162K. doi:10.1021/ja054811k. ISSN 0002-7863. PMID 16173741. Wacker, Michael; Feldman, Mario F.; Callewaert, Nico; Kowarik, Michael; Clarke, Bradley R.; Pohl, Nicola L.; Hernandez, Marcela; Vines, Enrique D.; Valvano, Miguel A.; Whitfield, Chris; Aebi, Markus (2006-05-02). "Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems". Proceedings of the National Academy of Sciences. 103 (18): 7088–7093. Bibcode:2006PNAS..103.7088W. doi:10.1073/pnas.0509207103. ISSN 0027-8424. PMC 1459022. PMID 16641107.
between −1.1 and −0.9. Recent simulation studies have shown that the variation in solvation energy between the ions and the surrounding water molecules underlies the mechanism of the Hofmeister series. Thus, ionic kosmotropes are characterized by strong solvation energy leading to an increase of the overall cohesiveness of the solution, which is also reflected by the increase of the viscosity and density of the solution.
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.